Multi-parametric MRI-based peritumoral radiomics on prediction of lymph-vascular space invasion in early-stage cervical cancer

Abstract

PURPOSEThis retrospective study aims to evaluate the use of multi-parametric magnetic resonance imaging (MRI) in predicting lymph-vascular space invasion (LVSI) in early-stage cervical cancer using radiomics methods.METHODSA total of 163 patients who underwent contrast-enhanced T1-weighted (CE T1W) and T2-weighted (T2W) MRI scans at 3.0T were enrolled between January 2014 and September 2019. Radiomics features were extracted and selected from the tumoral and peritumoral regions at different dilation distances outside the tumor. Mann–Whitney U test, the least absolute shrinkage and selection operator logistic regression, and logistic regression was applied to select the predictive features and develop the radiomics signature. Univariate analysis was performed on the clinical characteristics. The radiomics nomogram was constructed incorporating the radiomics signature and the selected important clinical predictor. Prediction performance of the radiomics signature, clinical model, and nomogram was evaluated with the area under the curve (AUC), specificity, sensitivity, calibration, and decision curve analysis (DCA).RESULTSA total of 5 features that were selected from the peritumoral regions with 3- and 7-mm dilation distances outside tumors in CE T1W and T2W MRI, respectively, showed optimal discriminative performance. The radiomics signature comprising the selected features was significantly associated with the LVSI status. The radiomics nomogram integrating the radiomics signature and degree of cellular differentiation exhibited the best predictability with AUCs of 0.771 (specificity (SPE)=0.831 and sensitivity (SEN)=0.581) in the training cohort and 0.788 (SPE=0.727, SEN=0.773) in the validation cohort. DCA confirmed the clinical usefulness of our model.CONCLUSIONOur results illustrate that the radiomics nomogram based on MRI features from peritumoral regions and the degree of cellular differentiation can be used as a noninvasive tool for predicting LVSI in cervical cancer.